UTMB develops a universal vaccine platform that’s cheaper and shelf stable
Researchers at The University of Texas Medical Branch at Galveston have developed a less expensive way to produce vaccines that cuts the cost of vaccine production and storage by 80 percent without decreasing safety or effectiveness. The findings are currently available in EBioMedicine.
Vaccines are the most effective way to prevent and eradicate infectious diseases. Currently, many vaccines have to be manufactured in cell culture or eggs, which is expensive and carries the risk of contaminations. In addition, most vaccines must be kept refrigerated during the transportation from manufacturers to health care clinics. In tropical and subtropical regions, such cold storage requirements could contribute to more than 80 percent of the vaccine cost.
“The ability to eliminate cell culture or eggs and cold storage will change the process of vaccine development,” said UTMB’s Pei-Yong Shi, professor in the department of biochemistry and molecular biology. “Importantly, this vaccine technology could potentially serve as a universal platform for development of live-attenuated vaccines for many viral pathogens.”
To achieve these goals, the UTMB team engineered a live-attenuated Zika vaccine in the DNA form. Once the DNA is delivered into our body, it launches the vaccine in our cells, leading to antibody production and other protective immunity. With this production method, there is no need to manufacture the vaccine in cell culture or eggs at factories. Because DNA molecules are shelf stable, the vaccine will not expire at warm temperatures and could be stockpiled at room temperature for years.
Using UTMB’s Zika vaccine as a model, the research group showed that the DNA platform worked very efficiently in mice. After a single low dose, the DNA vaccine protected mice from Zika virus infection, mother-to-fetus transmission during pregnancy and male reproductive tract infection and damage.
“This is the first study to demonstrate that, after a single low dose, a DNA vaccine could induce saturated protective immunity,” Shi said. “We will continue testing this promising Zika vaccine platform and then apply the platform to other viruses.”
The Latest on: Vaccine production
via Google News
The Latest on: Vaccine production
- The timetable for a coronavirus vaccine is 18 months. Experts say that's riskyon April 1, 2020 at 1:28 pm
At a March 26 White House briefing, Fauci stuck to his timeline, saying that he plans to expedite the process in part with a financial gamble: by encouraging companies to launch production even before ...
- British American Tobacco Claims It’s Close to a Plant-Based COVID-19 Vaccineon April 1, 2020 at 12:49 pm
The antigens are also allegedly room temperature stable, so doses wouldn't require refrigeration to stay effective. British American Tobacco hopes governments will assist with the process and posits ...
- Reynolds company testing tobacco's possible role in developing COVID-19 vaccineon April 1, 2020 at 12:45 pm
Kentucky BioProcessing says its biotechnology strategy "has several advantages over conventional vaccine production technology." Those include: * It could be safer given that tobacco plants can’t host ...
- British American Tobacco is trying to make a coronavirus vaccineon April 1, 2020 at 10:52 am
“Vaccine development is challenging and complex work ... Kentucky BioProcessing was involved in the production of ZMapp in 2014, a treatment that was tested with some success on Ebola patients in the ...
- Israeli scientists: ‘Active component’ of coronavirus vaccine days awayon April 1, 2020 at 10:51 am
A team of Israeli researchers says that they are days away from completing the production of the active component of a coronavirus vaccine that could be tested on humans as early as June 1. “We are in ...
- Johnson & Johnson partners with BARDA to fund $1 billion in COVID-19 vaccine researchon April 1, 2020 at 10:25 am
J&J said it had also committed to expanding its global manufacturing capacity, both in the U.S. and overseas. That additional production ability will help the company bring an affordable vaccine to ...
- This is no April Fool's. British American Tobacco is trying to make a coronavirus vaccineon April 1, 2020 at 10:19 am
The maker of Camel, Lucky Strike and Pall Mall cigarettes is trying its hand at a new product: a coronavirus vaccine.
- Global Cancer Vaccines Market Analysis to 2026 - Featuring Aduro BioTech, Astellas Pharma & AstraZeneca Among Others - ResearchAndMarkets.comon April 1, 2020 at 8:59 am
For more information about this report visit https://www.researchandmarkets.com/r/avgl7v ...
- Moderna Hopeful of Phase 1 Data for COVID-19 Vaccine by Summer, Analyst Reiterates Buyon April 1, 2020 at 8:55 am
The images of eerie empty streets, along with the sight of masked civilians roaming around, all add to the sense that we are currently on the set of a dystopian sci-fi movie. Add into the mix the race ...
via Bing News